COVID-19 Vaccinations in Adolescents (COVA Study)

The COVID-19 pandemic has caused more than 100 million cases and 3 million deaths globally, and over 10,000 cases in Hong Kong. The virus may cause long COVID and multisystem inflammatory syndrome in children. Some emerging virus variants have also been found to be more infectious to teenagers. Children and adolescents under 20 years old are contagious, and infected children may spread the virus to their grandparents. The prolonged suspension of classes and social distancing have also had a negative impact on students. Therefore, children and adolescents urgently need to be immunised against COVID-19. 

The Department of Paediatrics and Adolescent Medicine and School of Public Health at HKUMed are now launching the COVID-19 Vaccination in Adolescents (COVA) study.

Timely local data on the reactogenicity and immunogenicity of COVID-19 vaccines in adolescents will inform the public and the government whether the vaccines should be given to adolescents, and allow complete school reopening as soon as possible. This study has been approved by the Institutional Review Board of HKU/Hospital Authority HK West Cluster.

青少年2019冠狀病毒病疫苗研究(COVA)計劃

2019冠狀病毒病(COVID-19)大流行在全球造成超過1億宗病例, 300多萬人死亡,而在香港亦有高達1萬多宗病例。兒童感染新冠病毒後可能會導致後遺症和多系統炎症綜合症。有些變種病毒也發現對青少年有更大的感染力。此外,20歲以下的兒童和青少年有較高的傳染性,在家感染同住長者的情況不容忽視。長時間的停課和社交隔離措施亦已對學生造成不良的影響。 因此,兒童和青少年急需接種新冠病毒疫苗。

港大醫學院兒童及青少年科學系以及公共衞生學院現正開展青少年新冠病毒疫苗研究(COVA)。

有關COVID-19疫苗在青少年中的反應原性和免疫原性的本地數據,將適時通知公眾和政府,以決定應否把疫苗接種組別擴大至青少年,令學生可以早日復課。此研究已獲香港大學/醫管局香港西聯網研究倫理委員會批准。

Content | 研究內容

COVA will recruit 300 healthy adolescents and patients with immune disorders or prior COVID-19 aged 11 years or above, as well as their parents (and unrelated adult controls). At the moment, the families will be offered to receive the BioNTech/Fosun BNT162b2 or SinoVac's CoronaVac. Each family can freely choose the vaccine they receive, given each family member receives the same vaccine. Participants will report adverse reactions and other adverse events following immunisation, and be followed up for immunogenicity assessments and vaccine breakthrough COVID-19 over a period of 3 years. Participants are covered by the Hong Kong government’s COVID-19 vaccine indemnity fund. Recruitment is ongoing for patient groups, and those interested may refer to the registration and contact details below.

COVA將招募300名11歲以上的健康青少年和免疫力較低或曾感染2019年冠狀病毒病病人,及其父母和成年人作對照。目前,研究將向這些家庭提供復星醫藥/BioNTech 復必泰(BNT162b2)或科興克爾來福疫苗。每個家庭都可以自由選擇接種同一疫苗。參加者將在未來3年內進行隨訪,報告注射後的身體情況及不良反應,並抽血接受免疫原性評估和疫苗突破新冠病毒病。參加者受香港政府新冠疫苗保障基金的保護。上述有關病人組別的招募仍在進行中,有興趣的人士可以參考下方之報名與聯絡詳情。

Enquiries | 聯絡研究團隊

If you have any further question about this study, please contact HKU Department of Paediatrics and Adolescent Medicine:

如有任何查詢,請聯絡港大兒科:

+852 5944 5961
+852 5944 5961